ArticleThe Journal of clinical investigation2017
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.
Article in The Journal of clinical investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models - a comprehensive review.Drug delivery and translational research · 2025Review
- Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health.Microbial biotechnology · 2025Review
- Therapeutic Approaches of Viral Gene Silencing by Small Interfering RNA: Strategies to Prevent the Emergence of Antiviral Resistant Escape Mutants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Characterization of Ravn virus viral shedding dynamics in experimentally infected Egyptian rousette bats (Journal of virology · 2025Article
- An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.Expert opinion on drug discovery · 2024Review
- Advances in modification and delivery of nucleic acid drugs.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023Review
- Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Pathogenicity and virulence of Marburg virus.Virulence · 2022Review
- Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases.Journal of nanostructure in chemistry · 2022Review
- Combination therapy protects macaques against advanced Marburg virus disease.Nature communications · 2021Article
- Viral Vectors Applied for RNAi-Based Antiviral Therapy.Viruses · 2020Review
- A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967.Microbiology and molecular biology reviews : MMBR · 2020Review
- Recent advances in siRNA delivery mediated by lipid-based nanoparticles.Advanced drug delivery reviews · 2020Review
- Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.Accounts of chemical research · 2019Article
- Recent advances in marburgvirus research.F1000Research · 2019Review
- Distinct Biological Phenotypes of Marburg and Ravn Virus Infection in Macaques.The Journal of infectious diseases · 2018Article
- Post-exposure treatments for Ebola and Marburg virus infections.Nature reviews. Drug discovery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients. There are currently no licensed filovirus vaccines or antiviral therapies. The development of broad-spectrum therapies against members of the Marburgvirus genus, including Marburg virus (MARV) and Ravn virus (RAVV), is difficult because of substantial sequence variability. RNAi therapeutics offer a potential solution, as identification of conserved target nucleotide sequences may confer activity across marburgvirus variants. Here, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein-targeting (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or RAVV disease to mimic cases in which patients begin treatment for fulminant disease. Sixteen rhesus monkeys were lethally infected with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four or five days after infection and RAVV-infected animals starting treatment three or six days after infection. While all untreated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected macaques, even when treatment began just 1 day prior to the death of the control animals. In MARV-infected animals, day-4 treatment initiation resulted in 100% survival, and day-5 treatment resulted in 50% survival. These results identify a single siRNA therapeutic that provides broad-spectrum protection against both MARV and RAVV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.